However, for patients with breast tumors expressing low levels of HR, categorically defined as 1–9% of ER or 1–20% of PgR, it is recommended to add more aggressive treatments such as chemotherapy, with endocrine therapy, for the oncologic safety of the patients [15]. This evidence concerns the gene PGR and breast neoplasm.